Literature DB >> 25736960

Long-term kinetics of AA amyloidosis and effects of inflammatory restimulation after disappearance of amyloid depositions in mice.

N Muhammad1, T Murakami1,2, Y Inoshima1, N Ishiguro1.   

Abstract

Amyloid A (AA) amyloidosis is characterized by extracellular pathogenic deposition of insoluble fibril protein in various body organs. Deposited amyloid generally remains in a variety of organs for long periods, but its disappearance has been reported after the precursor protein is diminished. The kinetics of AA deposition are not completely understood and, in particular, the roles of cells and cytokines in the deposition and clearance of amyloid remain unclear. In this study, we investigated the disappearance of amyloid depositions in mice over a 1-year period. AA amyloidosis was induced experimentally in mice by injecting amyloid-enhancing factor (AEF) and silver nitrate. Mice were killed at different time-points to examine the occurrence and disappearance of amyloid depositions. Maximum levels of amyloid depositions were observed at 20 days after inoculation. Clearance of amyloid depositions was observed from the 40th day onwards, with only minute traces of amyloid present by 240 days. A second inflammatory stimulus consisting of AEF and silver nitrate was given at 330 or 430 days, after amyloid depositions had disappeared almost completely. After that, serum amyloid A was overproduced and redeposition of amyloid was observed, indicating that all mice were primed for aggressive amyloid depositions. After administration of the inflammatory stimuli, the proinflammatory environment was found to have increased levels of interleukin (IL)-6, while anti-inflammatory conditions were established by IL-10 as regression of amyloid deposition occurred. These results suggest that the proinflammatory and anti-inflammatory status have key roles in both amyloid deposition and clearance.
© 2015 British Society for Immunology.

Entities:  

Keywords:  AA-amyloid; SAA; cytokine; long-term kinetics; mice

Mesh:

Substances:

Year:  2015        PMID: 25736960      PMCID: PMC4469163          DOI: 10.1111/cei.12615

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis.

Authors:  Barbara Kluve-Beckerman; Joyce Hardwick; Lijing Du; Merrill D Benson; Brett P Monia; Andrew Watt; Rosanne M Crooke; Adam Mullick
Journal:  Amyloid       Date:  2011-08-10       Impact factor: 7.141

2.  A primed state exists in vivo following histological regression of amyloidosis.

Authors:  P N Hawkins; M B Pepys
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

3.  Increased frequency of T cells expressing IL-10 in Alzheimer disease but not in late-onset depression patients.

Authors:  Karen Cecília Torres; Patrícia Araújo Pereira; Giselle Sabrina Lima; Isadora Cristina Bozzi; Vitor Bortolo Rezende; Maria Aparecida Bicalho; Edgar Nunes Moraes; Débora Marques Miranda; Marco Aurélio Romano-Silva
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-08-13       Impact factor: 5.067

Review 4.  Biology of interleukin-10.

Authors:  Robert Sabat; Gerald Grütz; Katarzyna Warszawska; Stefan Kirsch; Ellen Witte; Kerstin Wolk; Jens Geginat
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-05       Impact factor: 7.638

5.  Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression.

Authors:  Keisuke Hagihara; Teppei Nishikawa; Yasuhiro Sugamata; Jian Song; Tomoyasu Isobe; Tetsuya Taga; Kazuyuki Yoshizaki
Journal:  Genes Cells       Date:  2005-11       Impact factor: 1.891

Review 6.  Cross currents in protein misfolding disorders: interactions and therapy.

Authors:  Rodrigo Morales; Kristi M Green; Claudio Soto
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-11       Impact factor: 4.388

7.  Murine amyloid protein AA in casein-induced experimental amyloidosis.

Authors:  M Skinner; T Shirahama; M D Benson; A S Cohen
Journal:  Lab Invest       Date:  1977-04       Impact factor: 5.662

8.  Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology.

Authors:  Terrence Town; Yasmina Laouar; Christopher Pittenger; Takashi Mori; Christine A Szekely; Jun Tan; Ronald S Duman; Richard A Flavell
Journal:  Nat Med       Date:  2008-06-01       Impact factor: 53.440

9.  The role of NF-kappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6.

Authors:  J C Betts; J K Cheshire; S Akira; T Kishimoto; P Woo
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

10.  A concise review of amyloidosis in animals.

Authors:  Moges Woldemeskel
Journal:  Vet Med Int       Date:  2012-03-15
View more
  2 in total

1.  Longitudinal study of experimental induction of AA amyloidosis in mice seeded with homologous and heterologous AA fibrils.

Authors:  Naeem Muhammad; Tomoaki Murakami; Yasuo Inoshima; Naotaka Ishiguro
Journal:  Inflamm Res       Date:  2016-05-10       Impact factor: 4.575

2.  Experimental transmission of systemic AA amyloidosis in autoimmune disease and type 2 diabetes mellitus model mice.

Authors:  Mayuko Maeda; Tomoaki Murakami; Naeem Muhammad; Yasuo Inoshima; Naotaka Ishiguro
Journal:  Exp Anim       Date:  2016-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.